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Philadelphia chromosome negative myeloproliferative neoplasms (Ph-MPNs) are rare 
clonal hematological malignancies mainly, including polycythemia vera (PV), 
essential thrombocythemia (ET) and myelofibrosis (MF). Patients with these diseases 
run a high risk of vascular complications and may transform to acute myeloid 
leukemia (AML). Population-based studies relating to these issues are few in number. 
The aims were (i) to investigate the rate of AML development in subtypes of Ph-
MPNs, (ii) to determine whether clinical and bone marrow findings at diagnosis have 
an impact on survival and vascular complications in PV and ET, (iii) to find 
prognostic tools based on clinical findings in newly diagnosed PV and (iv) to describe 
the “real”- life data from newly diagnosed PV and ET. We have investigated these 
issues in population-based material; the first and the third studies were based on 
patients from both Gothenburg, Sweden, and the Côte d`Or area, France, and the 
second study was population-based from Gothenburg and the fourth study comprised 
PV and ET patients in the National MPN Registry. 
In the median observation period of 15 years, 7% (56 of 795) of patients with Ph-MPN 
transformed to AML. The yearly rate of AML transformation was significantly higher 
in MF (1.09%) compared with that of ET (0.37%) and PV (0.38%); (p = 0.02 and p = 
0.002 respectively). Patients with PV had a significantly shorter survival compared 
with the general Swedish population (HR 1.66; CI:(1.38-1.99); p < 0.001). For ET, 
however, the corresponding survival differences did not reach statistical significance 
(HR 1.23; CI:(0.97-1.51); p = 0.089). Low hemoglobin at the time of diagnosis 
predicted poor survival in ET (p = 0.0281) and splenomegaly predicted poor survival 
in PV (p = 0.037). Using multivariate analysis, independent risk factors at diagnosis 
for survival in PV patients were identified as: age > 70 years, WBC > 13 × 109/L and 
thrombotic events. Patients with none of these risk factors had a 10-year relative 
survival (RS) of 84%, compared with 59% and 26% in patients with one and two or 
three risk factors respectively.  
In the fourth study, we showed that vascular complications preceded MPN diagnosis 
in 35% of ET and 37% of PV and multivariate analysis identified low hemoglobin as a 
risk factor for thromboembolic complications in PV (p = 0.012), while in ET age > 65 
years, WBC > 12 × 109 /L and the presence of the JAK2 V617F mutation were 
independent risk factors (p = 0.0004, p = 0.0038 and p = 0.0016 respectively). 
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